Exact Sciences (EXAS) Beats Q3 EPS by 6c, FY Revenue Guidance Tops Views
Get Alerts EXAS Hot Sheet
Price: $58.86 --0%
EPS Growth %: -14.3%
Financial Fact:
Product royalty fees: 12.17M
Today's EPS Names:
DSGN, ATRA, CRVS, More
EPS Growth %: -14.3%
Financial Fact:
Product royalty fees: 12.17M
Today's EPS Names:
DSGN, ATRA, CRVS, More
Join SI Premium – FREE
Exact Sciences (NASDAQ: EXAS) reported Q3 EPS of ($0.36), $0.06 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $28.1 million versus the consensus estimate of $25.1 million.
- reported completing 68,000 Cologuard tests vs consensus of 65,400 tests
GUIDANCE:
Exact Sciences sees FY2016 revenue of $93-95 million, versus the consensus of $90.9 million.
- reiterated our FY 2016 guidance of completing approximately 240,000 Cologuard tests
For earnings history and earnings-related data on Exact Sciences (EXAS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FreightCar America (RAIL) Misses Q4 EPS by 6c, provides guidance
- Embraer (ERJ) Tops Q4 EPS by 43c; offers guidance
- Augmedix, Inc. (AUGX) Tops Q4 EPS by 1c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!